Premium
Decreased survival in diabetic patients with heart failure due to systolic dysfunction ☆
Author(s) -
Kamalesh Masoor,
Subramanian Usha,
Sawada Stephen,
Eckert George,
Temkit M'Hamed,
Tierney William
Publication year - 2006
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1016/j.ejheart.2005.10.005
Subject(s) - medicine , heart failure , diabetes mellitus , diuretic , loop diuretic , cardiology , outpatient clinic , prospective cohort study , ace inhibitor , beta blocker , creatinine , blood pressure , angiotensin converting enzyme , endocrinology
Background: Prognosis of patients with heart failure (HF) has improved in recent years due to advances in therapy. Whether this is also true for diabetic subjects with HF in clinical practice has not been studied in a prospective manner. Methods: All patients with HF and left ventricular systolic dysfunction attending the outpatient clinic at our Veteran's Hospital between October 1999 and November 2000 were enrolled in our study and followed prospectively. Electronic medical records were accessed for data on comorbid conditions, medications, echocardiogram results and mortality information. Mean follow‐up was 2.7 years. Results: Of 495 patients with HF due to systolic dysfunction enrolled in the study, 293 (59%) had diabetes. Prevalence of hypertension, diuretic use and angiotensin converting enzyme inhibitor use was higher among diabetics. Beta‐blocker usage was equal and high in both groups (60%). On follow‐up, 109/273 (37%) patients in the diabetic group died, compared with 49/202 (24%) in the non‐diabetic group. Independent predictors of death were diabetes ( p <0.005, OR=1.73), age at enrollment ( p <0.0001, OR=1.06), serum creatinine ( p <0.01, OR=1.44) and diuretic use ( p =0.038, OR=1.85). Beta‐blocker use was associated with a decreased risk of death on univariate analysis only. Conclusions: Our results show that diabetic patients with HF continue to have higher mortality than non‐diabetic patients with HF despite advances in therapy.